MarketCap
Facebook
X
Telegram
Oncternal Therapeutics ROE Ratio | ONCT
Annual ROE Ratio Oncternal Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -131.37 | -72.45 | -35.56 | -15.25 | -238.88 | 22.2 | 39.85 | -89.11 | -1006.08 | -221.05 | -394.15 | -56.76 | -46.32 | 29.57 | 528.64 | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 528.64 | -1006.08 | -112.45 |
Quarterly ROE Ratio Oncternal Therapeutics
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -210.1 | -137.42 | -104.97 | -68.39 | -84.62 | -73.82 | -66.33 | -44.45 | -54.64 | -45.9 | -35.53 | -23.18 | -51.17 | -98.65 | -136.73 | -131.24 | -158.19 | -229.81 | -200.01 | -154.43 | -136.16 | -139.66 | -65.19 | -92.1 | -70.52 | -58.32 | -108.7 | -98.0 | -172.36 | -209.93 | -167.22 | -114.25 | -253.65 | 610.75 | 796.72 | 772.83 | 865.16 | 10.1 | -214.67 | -235.49 | -206.68 | -211.9 | -175.19 | -139.37 | -161.83 | -96.71 | -65.08 | -48.12 | -40.52 | -64.35 | -56.17 | -41.84 | -11.47 | -11.9 | -3.61 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 865.16 | -253.65 | -45.91 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AbbVie
ABBV
|
-55.54 | $ 263.04 | 0.49 % | $ 465 B |  USA |
 |
AbCellera Biologics
ABCL
|
-15.14 | $ 11.41 | 2.15 % | $ 3.41 B |  Canada |
 |
Фармсинтез
LIFE
|
-51.75 | - | - | - |  Russia |
 |
Aclaris Therapeutics
ACRS
|
-62.98 | $ 5.53 | 6.02 % | $ 678 M | USA |
 |
ADC Therapeutics SA
ADCT
|
76.75 | $ 1.09 | 3.74 % | $ 139 M |  Schweiz |
 |
Amryt Pharma plc
AMYT
|
0.28 | - | - | $ 621 M |  Britain |
 |
Evelo Biosciences
EVLO
|
2294.21 | - | -14.46 % | $ 27.9 M | USA |
 |
Allakos
ALLK
|
-146.95 | - | - | $ 28.6 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
-88.4 | - | - | $ 231 M | USA |
 |
Clovis Oncology
CLVS
|
23.09 | - | -7.23 % | $ 13 M | USA |
 |
Chimerix
CMRX
|
-72.64 | - | - | $ 756 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
-71.33 | - | - | $ 401 M | USA |
 |
ADMA Biologics
ADMA
|
30.78 | $ 8.61 | 0.16 % | $ 2.05 B | USA |
 |
Eiger BioPharmaceuticals
EIGR
|
518.49 | - | -9.21 % | $ 2.55 M | USA |
|
89bio
ETNB
|
-91.59 | - | - | $ 1.55 B | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
-169.75 | - | - | $ 384 M | Britain |
 |
Fusion Pharmaceuticals
FUSN
|
-42.65 | - | - | $ 1.41 B | Canada |
 |
Guardion Health Sciences
GHSI
|
1.94 | - | -0.31 % | $ 3.64 M | USA |
 |
Genocea Biosciences
GNCA
|
-122.61 | - | -15.0 % | $ 3.04 M | USA |
 |
Gritstone Oncology
GRTS
|
-267.1 | - | 0.42 % | $ 213 M | USA |
 |
G1 Therapeutics
GTHX
|
-135.55 | - | - | $ 370 M | USA |
 |
Harpoon Therapeutics
HARP
|
-1254.51 | - | - | $ 763 M | USA |
 |
Humanigen
HGEN
|
151.25 | - | -81.12 % | $ 4.28 M | USA |
 |
HOOKIPA Pharma
HOOK
|
-84.94 | - | -6.92 % | $ 79.4 M | USA |
 |
Intercept Pharmaceuticals
ICPT
|
-22.37 | - | - | $ 643 M | USA |
 |
IGM Biosciences
IGMS
|
-406.45 | - | - | $ 76.9 M | USA |
 |
IMV
IMV
|
575.45 | - | - | $ 13.1 M | Canada |
 |
Intra-Cellular Therapies
ITCI
|
-1.47 | - | - | $ 13.6 B | USA |
 |
Kinnate Biopharma
KNTE
|
-70.7 | - | - | $ 123 M | USA |
 |
Chinook Therapeutics
KDNY
|
-42.51 | - | - | $ 2.6 B | USA |
 |
Kaleido Biosciences
KLDO
|
-851.21 | - | -3.69 % | $ 12.4 M | USA |
 |
Kronos Bio
KRON
|
-98.29 | - | 1.49 % | $ 50.8 M | USA |
 |
Karuna Therapeutics
KRTX
|
-34.58 | - | - | $ 12.2 B | USA |
 |
Landos Biopharma
LABP
|
-69.0 | - | 0.58 % | $ 144 M | USA |
 |
La Jolla Pharmaceutical Company
LJPC
|
-29.46 | - | - | $ 154 M | USA |
 |
LogicBio Therapeutics
LOGC
|
-130.27 | - | - | $ 229 M | USA |
 |
Lumos Pharma
LUMO
|
-124.64 | - | - | $ 35.3 M | USA |
 |
Merrimack Pharmaceuticals
MACK
|
-6.3 | - | - | $ 216 M | USA |
 |
Stealth BioTherapeutics Corp
MITO
|
115.97 | - | - | $ 23.9 M | USA |
 |
Mirati Therapeutics
MRTX
|
-74.35 | - | - | $ 3.3 B | USA |
 |
NexImmune
NEXI
|
-921.57 | - | 70.13 % | $ 4.12 M | USA |
 |
9 Meters Biopharma
NMTR
|
-1823.19 | - | -42.97 % | $ 1.05 M | USA |
 |
InVivo Therapeutics Holdings Corp.
NVIV
|
-66.62 | - | -37.48 % | $ 476 K | USA |
 |
Nymox Pharmaceutical Corporation
NYMX
|
66.3 | - | -19.68 % | $ 18.4 M | Canada |
 |
ObsEva SA
OBSV
|
-993.13 | - | -15.52 % | $ 10.5 M | Schweiz |
 |
Oncorus
ONCR
|
-127.92 | - | -8.54 % | $ 3.19 M | USA |
 |
OncoSec Medical Incorporated
ONCS
|
-558.64 | - | 31.87 % | $ 1.61 M | USA |
 |
Opiant Pharmaceuticals
OPNT
|
6.42 | - | - | $ 109 M | USA |
 |
Orchard Therapeutics plc
ORTX
|
-153.32 | - | 1.02 % | $ 90.8 M | Britain |